



Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Expert faculty will discuss new developments in the care of patients with HER2-positive advanced breast cancer. Participants will get up to date insights from expert faculty novel therapeutic agents and strategies utilizing antibody-drug conjugates for patients after failure of standard-of-care treatments.

Agenda

- **Novel Anti-HER2-Directed ADCs**
 - New & emerging HER2-directed ADCs
 - Novel combinations
- **Novel Targeted Therapies for MBC**
 - Tyrosine kinase inhibitors
 - Novel Anti-HER2 Monoclonal Antibody
- **Case Discussion: Medical Need for Novel HER2-Directed Options After Failure on Standard-of-Care Treatments**
- **Final Thoughts and Summary**

Faculty Presenters

Adam Brufsky, MD | Program Director
Professor of Medicine, Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, USA

Thomas Bachelot, MD, PhD
Director, Breast Cancer Unit
Centre Léon Bérard,
Lyon, France

Cristina Saura, MD, PhD
Head, Breast Cancer Unit
Medical Oncology Service
Vall d'Hebron University Hospital
Barcelona, Spain



Provided by Clinical Care Options, LLC.



In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education:
CCO designates this live activity or enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Supported by an educational grant from Daiichi Sankyo Inc.